TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Tony S K Mok et al.PubMed ↗Publisher ↗

No numbers read from the abstract.